Estimation of glomerular filtration rate in dogs by plasma clearance of gadolinium diethylenetriamine pentaacetic acid as measured by use of an ELISA

American Journal of Veterinary Research

Volumn 70, Issue 4, 2009, Pages 547-552

  Nolan, Benjamin G ^a   Ross, Linda A ^a   Vaccaro, Dennis E ^b   Groman, Ernest V ^b   Reinhardt, Christopher P ^b  

^a TUFTS UNIVERSITY   (United States)

^b BioPhysics Assay Laboratory Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; IOHEXOL;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; KIDNEY DISEASE; MALE; NONHUMAN; PLASMA CLEARANCE; POLYDIPSIA; POLYURIA; SENSITIVITY ANALYSIS;

ANIMALS; CONTRAST MEDIA; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GADOLINIUM DTPA; GLOMERULAR FILTRATION RATE; MALE; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 65349127062     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.70.4.547     Document Type: Article

References (26)

1. Finco DR. Kidney functions. In: Kaneko JJ, Harvey JW, Bruss ML, eds. Clinical biochemistry of domestic animals. New York: Academic Press Inc, 1997;441.
2. Dworkin LD, Brenner BM. Biophysical basis of glomerular filtration. In: Seldin DW, Giebisch G, eds. The kidney: physiology and pathophysiology. New York: Lippincott, Williams & Wilkins, 2000; 763.
3. Finco DR, Tabaru H, Brown SA, et al. Endogenous creatinine clearance measurement of glomerular filtration rate in dogs. Am J Vet Res 1993;54:1575-1578.
4. Finco DR, Brown SA, Crowell WA, et al. Exogenous creatinine clearance as a measure of glomerular filtration rate in dogs with reduced renal mass. Am J Vet Res 1991;52:1029-1032.
5. Finco DR, Braselton WE, Cooper TA. Relationship between plasma iohexol clearance and urinary exogenous creatinine clearance in dogs. J Vet Intern Med 2001;15:368-373.
6. Watson ADJ, Lefebvre HP, Concordet D, et al. Plasma exogenous creatinine clearance test in dogs: comparison with other methods and proposed limited sampling strategy. J Vet Intern Med 2002;16:22-33.
7. Twardock AR, Krawiec DR, Itkin RJ. Renal imaging I & II: functional renal scintigraphy. In: Berry CR, Daniel GB, eds. Handbook of veterinary nuclear medicine. Raleigh, NC: North Carolina State University 1996;122-132.
8. 99mTc-diethylenetriaminepentaacetic acid nuclear imaging for quantitative determination of the glomerular filtration rate in dogs. Am J Vet Res 1986;47:2175-2179.
9. Tsushima Y. Functional CT of the kidney. Eur J Radiol 1999;30:191-197.
10. O'Dell-Anderson KJ, Twardock AR, Grimm JB, et al. Determination of glomenilar filtration rate in dogs using contrast-enhanced computed tomography. Vet Radiol Ultrasound 2006;47:127-135.
11. Brown SA, Finco DR, Boudinot FD, et al. Evaluation of a single injection method, using iohexol, for estimating glomerular filtration rate in cats and dog. Am J Vet Res 1996;57:105-110.
12. Finco DR. Measurement of glomerular filtration rate via urinary clearance of inulin and plasma clearance of technetium Tc 99m pentetate and exogenous creatinine in dogs. Am J Vet Res 2005;66:1046-1055.
13. Hackstein N, Kooijman H, Tomaselli S, et al. Glomerular filtration rate measured using Patlak plot technique and contrast-enhanced dynamic MRI with different amounts of gadolinium-DTPA. J Magn Reson Imaging 2005;22:406-414.
14. Weinmann HJ, Brasch RC, Press WR, et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984;142:619-624.
15. Weinmann HJ, Laniado M, Mützel W. Pharmacokinetics of GdDTPA/ dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167-182.
16. Anderson DJ. Determination of the lower limit of detection. Clin Chem 1989;35:2152-2153.
17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986;1:307-310.
18. Saftiel Y, Ali M, Hayt M, et al. Gadolinium use in spine procedures for patients with allergy to iodinated contrast - experience of 127 procedures. AJNR Am J Neuroradiol 2006;27:1194-1197.
19. Grobner T, Prischl FC. Gadoliniurn and nephrogenic systemic fibrosis. Kidney Int 2007;72:260-264.
20. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
21. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586-592.
22. Deo A, Fogel M, Cowper S. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264-267.
23. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
24. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
25. Wahba IM, Simpson EL, White K. Gadolinium not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007;7:2425-2432.
26. US FDA Center for Drug Evaluation and Research. information on gadolinium-containing contrast agents. (Updated 23 May 2007). Available at: www.fda.gov/cder/drug/infopage/gcca/default.htm. Accessed Jan 7, 2008.